RxDoctor Payments DataLook up a doctor →

Stanley Cohen, MD

Rheumatology · Dallas, TXNPI 1366441958

Payments from drug & device makers

$1,888,108in general payments, 2019–2025

Across 794 payments — averaging $2377.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$593K
  • Pacira Therapeutics, Inc.$422K
  • Pfizer$401K
  • Eli Lilly$102K
  • Regeneron$92K
  • Astrazeneca UK Limited$49K
  • plus $229K from 34 others
$55,293in research payments, 2019–2025

Across 39 payments — averaging $1417.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$54K
  • F. Hoffmann-la Roche AG$2K
  • Amgen$167

What the payments were for

  • Consulting fees$187,62659%
  • Speaking & faculty fees$110,36035%
  • Travel & lodging$9,4783%
  • Food & beverage$10,4083%
  • Education$360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,888,108 in reported general payments places this provider in the 95th percentile of 512 rheumatology providers in Texas.

See all rheumatology providers in Texas

Medicare billing

Part B allowed, 2024
$745,180
Medicare patients
595
Services billed
67,923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept141$1,057,945
Humira(Cf) PenAdalimumab49$447,022
EnbrelEtanercept53$389,379
Xeljanz XrTofacitinib Citrate28$196,270
RinvoqUpadacitinib18$142,403
Cosentyx Sensoready (2 Pens)Secukinumab13$112,299
Orencia ClickjectAbatacept19$101,650
Cimzia (2 Pack)Certolizumab Pegol11$60,661
Actemra ActpenTocilizumab13$58,974
Hydroxychloroquine Sulfate342$13,543
MethotrexateMethotrexate Sodium448$13,525
RasuvoMethotrexate/Pf19$12,991
Celecoxib289$8,382
Prednisone441$3,345
Mycophenolate Mofetil39$2,867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$593,257$389,37953 claims
AbbVieRinvoq$23,750$142,40318 claims
UCB, Inc.Cimzia (2 Pack)$21,539$60,66111 claims
Medexus Pharma, Inc.Rasuvo$63$12,99119 claims
Scilex Pharmaceuticals Inc.Colchicine$18$1,73047 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 512 rheumatology providers in Texas.

Other rheumatology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →